We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02674399
Recruitment Status : Completed
First Posted : February 4, 2016
Results First Posted : July 13, 2021
Last Update Posted : August 10, 2021
Sponsor:
Collaborator:
KCRN Research, LLC
Information provided by (Responsible Party):
Nature Cell Co. Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study is a double-blind, randomized, controlled study with two arms to evaluate JointStem as a treatment for subjects with osteoarthritis. Following a 2-week screening period, approximately 30 subjects will be randomly assigned into one of the following two arms in a 2:1 ratio (2 JointStem : 1 positive control). After each subject completes 6-month visit (Visit 6) and the data management team confirms all data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.Only subjects who are assigned will be requested to visit the study center for 9-month and 12-month follow-up visits (Visits 7 and 8). To see long-term effects of JointStem, all subjects who complete Visit 6 will be requested to visit the study center at 24-month after the injection.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Drug: JointStem Drug: Synvisc-One Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Treatment of Osteoarthritis
Actual Study Start Date : February 16, 2016
Actual Primary Completion Date : March 12, 2018
Actual Study Completion Date : December 28, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: JointStem
autologous adipose tissue derived mesenchymal stem cells (AdMSC)
 Drug: JointStem
Active Comparator: Synvisc-One
hyaluronic acid
 Drug: Synvisc-One
Other Name: Active Comparator


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group [ Time Frame: Baseline and 6 months ]
    Comparing the baseline and 6-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment

  2. Change From Baseline on Visual Analog Scale (VAS) in JointStem Group [ Time Frame: Baseline and 6 months ]
    Comparing the baseline and 6-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.

  3. MRI Improvement Evaluation in JointStem Group [ Time Frame: 6 months ]
    Comparing the baseline and 6-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.


Secondary Outcome Measures :
  1. Change From Baseline on WOMAC Between JointStem and Positive Control Groups [ Time Frame: Baseline and 6 months ]
    Comparing the changes of WOMAC scores between JointStem and positive control groups at 6 months Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment

  2. Change From Baseline on VAS Between JointStem and Positive Control Groups [ Time Frame: Baseline and 6 months ]
    Comparing the changes of VAS scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.

  3. Change From Baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups [ Time Frame: Baseline and 6 months ]
    Comparing the changes of KOOS values between JointStem and positive control groups at 6 months KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment

  4. Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups [ Time Frame: Baseline and 6 months ]
    Comparing the changes of Lysholm Knee Scoring Scales between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment

  5. Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups [ Time Frame: Baseline and 6 months ]
    Comparing the changes of IKDC scores between JointStem and positive control groups at 6 months IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment

  6. Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups [ Time Frame: Baseline and 6 months ]
    Comparing the changes of RAND-36 scores between JointStem and positive control groups at 6 months Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment

  7. Change From Baseline on WOMAC in JointStem Group [ Time Frame: Baseline, 9 months and 12 months ]
    Comparing the baseline and 9-month/12-month WOMAC scores in JointStem group Score range: 0-2,400 A score of 2,400 represents the most severe impairment and 0 represents the least impairment

  8. Change From Baseline on VAS in JointStem Group [ Time Frame: Baseline, 9 months and 12 months ]
    Comparing the baseline and 9-month/12-month VAS scores in JointStem group Score range: 0-100 A score of 100 represents the most severe pain and 0 represents the least pain.

  9. Comparison of MRI Improvement Evaluation in JointStem Group [ Time Frame: Baseline, 6 months and 12 months ]
    Comparing the baseline and 9-month/12-month MRI improvement values in JointStem group MRI Improvement Evaluation was conducted by an MRI analysis company called 'Qmetrics'. The main radiological features evaluated were bone marrow edema, osteophytes, and cartilage. Certain features, such as the appearance of a new cartilage defect or increase in the size of existing cartilage defects or osteophytes, is generally considered an indication of osteoarthritic progression. Similarly, the diminishing in severity or size of existing abnormalities would generally be considered to be a healing(improving) response.

  10. Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12 [ Time Frame: Baseline, 6 months, 9 months and 12 months ]
    Comparing the baseline and 6-month/9-month/12-month Lysholm Knee Scoring Scale in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment

  11. Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group [ Time Frame: baseline, 6 month, 9 month, 12 month ]
    Comparing the baseline and 6-month/9-month/12-month KOOS scores in JointStem group KOOS score = 100 - [{(average score of each item) * 100} / 4 ] Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment

  12. Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group [ Time Frame: baseline, 6 month, 9 month, 12 month ]
    Comparing the baseline and 6-month/9-month/12-month IKDC scores in JointStem group IKDC score = {(sum of each item score) / 87} * 100 Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment

  13. Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group [ Time Frame: baseline, 6 month, 9 month, 12 month ]
    Comparing the baseline and 6-month/9-month/12-month RAND-36 scores in JointStem group Score range: 0-100 A score of 0 represents the most severe impairment and 100 represents the least impairment


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject who can give written informed consent
  • Male or female of any race, aged 22-60
  • Subject who had osteoarthritis of knee diagnosed at least six months prior to Screening
  • Subject who has joint pain ≥ 40mm on VAS (Visual Analog Scale) at Screening
  • Subject who has swelling, tenderness and active range of motion ≥ Grade I at Screening
  • Subject who seeks invasive interventions of intra-articular injections
  • Subject who is willing to discontinue all pain medications for osteoarthritis except rescue medication (< acetaminophen 3.25 g per day) at least 72 hours prior to screening and throughout the duration of study
  • Subject who has radiographic evidence of grade 3 to 4 osteoarthritis based on the Kellgren and Lawrence radiographic criteria.
  • Female subject who is neither pregnant nor lactating
  • Subject who is able to comply with lifestyle guidelines, scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  • Subject who has Body Mass Index (BMI) > 35 kg/m2
  • Subject who has unstable knees
  • Subject who took any NSAID within two weeks from Screening
  • Subject who had any intra-articular injection therapy in any joint within 2 months from Screening
  • Subject who has any clinically significant disease, which is judged by the investigator to affect this clinical trial
  • Subject who has inflammatory arthropathy (rheumatoid, psoriatic, or avascular necrosis), and post traumatic or septic arthritis
  • Subject who has chondrocalcinosis, Paget's disease, Villonodular synovitis, and other non-OA joint diseases
  • Subject who has HIV/viral hepatitis
  • Subject who had knee surgery or radiation therapy in the affected joint within 6 months from Screening
  • Subject who had CVA attack within 6 months from Screening
  • Subject for whom the investigator judges the liposuction can cause any problem
  • Subject who has significant lab abnormalities
  • Subject who has history of local anesthetic allergy
  • Subject who took immunosuppressants such as Cyclosporin A or azathioprine within 6 weeks from Screening
  • (If a subject uses aspirin or plavix) Subject for whom it is determined that it would not be safe to stop the aspirin/plavix therapy for 2 weeks prior to Visit 2
  • Subject who uses anticoagulants which cannot be stopped or corrected
  • Subject who had oral or intra-muscular corticosteroids within 30 days from Visit 2
  • Subject who had intra-articular corticosteroid injection in any joint within 30 days from Visit 2
  • Subject who had intra-articular hyaluronic acid injection within 30 days from Visit 2
  • Subject who has known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate) preparations or gram positive proteins
  • Subject who has knee joint infections or skin diseases or infections in the area of the injection site
  • Subject who has known systemic bleeding disorders
  • Subject who is an active drug/EtOH abuser
  • Subject who was enrolled in any other clinical trials within 2 months from Screening
  • Subject who the principal investigator considers inappropriate for the study due to any other reasons than those listed above
  • Subject whose MRI scan results at screening do not demonstrate any sign of cartilage damage
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02674399


Locations
Layout table for location information
United States, California
Orthopedic Pain Specialists
Santa Monica, California, United States, 90404
Walnut Creek, California, United States, 94598
Sponsors and Collaborators
Nature Cell Co. Ltd.
KCRN Research, LLC
  Study Documents (Full-Text)

Documents provided by Nature Cell Co. Ltd.:
Study Protocol  [PDF] May 14, 2018
Statistical Analysis Plan  [PDF] April 5, 2018
Informed Consent Form  [PDF] May 30, 2018

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Nature Cell Co. Ltd.
ClinicalTrials.gov Identifier: NCT02674399    
Other Study ID Numbers: JS-OAP2-US01
First Posted: February 4, 2016    Key Record Dates
Results First Posted: July 13, 2021
Last Update Posted: August 10, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
 Rheumatic Diseases
Hylan
Viscosupplements
Protective Agents
Physiological Effects of Drugs